In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Value of Scale in Pharma's Future

Executive Summary

Despite the increasingly common perception of the helpless mega-merged giant, vastly increased scale can provide such companies with significant competitive advantages, from which companies were unwilling or unable to benefit in the past. The largest companies, structured properly, should be able to discover disproportionately more compounds; develop them faster; and market them more successfully. But to reap these benefits, the super heavyweight pharmas will, paradoxically, have to learn how to think small.

You may also be interested in...



Too Big To Succeed: Where Are Large Pharmas Heading?

Company scale is a negative predictor of value creation among biopharmaceutical companies, says a new analysis by L.E.K. Consulting, and industry’s largest companies have simply become too large to generate significant shareholder return going forward. How can the largest pharmaceutical companies adapt to an environment where they’ve become too big to succeed?

Pharmaceutical M&A: Creating Value?

Observers and investors are placing their bets on the outcome of Europe's first hostile pharma bid, Sanofi-Synthelabo's proposed takeover of Aventis, and on whether the resulting entity would indeed be able to thrive against competitors such as GSK and Pfizer. But even against the checkered backdrop of past pharmaceutical mergers, it remains unclear whether Sanofi can achieve even an average amount of savings from such a deal.

Some Troubling Numbers For Big Pharma Consolidation

A recent CenterWatch Inc. study of 11 major pharmaceutical company mergers suggests that the downturn in sales and marketing figures for consolidated firms is accompanied by decreased R&D output.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

OM003971

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel